Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs V.BTI


Primary Symbol: V.BTI.H Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by JDavenporton Mar 23, 2021 12:03pm
171 Views
Post# 32858322

Don't be silly...

Don't be silly...Sometimes the over-the-top efforts to be negative on this forum border on the silly. This warrant extension by Bioasis is the right and proper thing to do. Even if great news comes out today and causes the share price to double, or move to almost a dollar, the warrants would needlessly expire unexercised. Further, the company has a right to force the exercising of the warrants if the price goes over $1.50 for 10 days. That right would expire with the warrants. Either way, serious money would be lost by the company and opportunity would be needlessly lost to the warrant holders.

The investors who bought the financing behind these warrants are longtime (long...!) investors in and supporters of Bioasis. Those warrants have value to them. They don't need to be knee-capped by an expiration.

As far as I'm concerned, the Bioasis story got restarted, reloaded and reset less than 9 months ago with signing of the Chiesi deal. Before that, this thing was, if not roadkill, at least road wounded. With no money Bioasis could make no moves, do no studies nor generate any news. Now we have at least 23 drug/disease combinations in play with data expected imminently, thanks to the money brought in by DrDR.

To make a statement that the prudent extension of the warrants' expiry date, and even the lowering of the hit price, together mean that Bioasis will have no news for an extended period is a logical fallacy not worthy of serious investors.

I have more to say elsewhere about this and other important things.

You know, Bioasis is starting to be a fun thing to watch, and certainly a fun thing for me to write about. Too many of you are so negative, and purposefully trying to be negative, that you're missing the real stuff that's going on. You'll see what I mean soon enough.

jd


<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse